QGEN WeeklyNYSE:QGEN weekly gave a bullish engulfing at the 5 and 20 EMA crossover along with MACD crossing up. This is after a triple bottom process around $46.
QIA trade ideas
Qiagen NV 🧙Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).
If you want not to miss ideas like this one ,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
QGEN (Qiagen N.V) - Bullish quarterly outlookQiagen N.V
Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.
Analysis/Commentary
Strong EPS and Sales Growth Y-on-Y
Based on the study of the previous quarterly earnings reports and subsequent price moves:
- Current quarter has started well, however, we have an opportunity for pull-back now and entry
- Looking for a price closer to the LOW point, confirmed by Slo Stochastic
- Expectation for the price to then move to MID or HIGH point
- Trailing stop-loss on price above MID point
GOOD LUCK.
DO YOUR OWN RESEARCH!
The Perception of QIAGEN DailyHello traders, QIAGEN is in a bullish push with sellers rejecting a buy candle and low bull volume. On the TIMEFRAME 30 15 Min a bull hammer move and in the 5 1 Min is in bullish continuity. Great likelihood of starting on the next high which corresponds to the middle of the median. And if the buyers are still in the game, we can reach the next high.
Please LIKE & FOLLOW, thank you!
Great Look for QGENLoving this setup. QGEN has struggled with this level for over a year. Recently it has consolidated with very tight price action and low volume at the highs. Volume has started to come in over the last two days as it looks to make a run for it. A good swing trade candidate. A move below $41 would have me out of the position. Earnings are out of the way so no major news events on the horizon.
Shot in the darkThis stock has a ton of positive hype surrounding it because of the 'rona. Nonetheless, the chart screams institutional liquidation to me. This is a gut feeling and I could easily be wrong a hundred fold. Something doesn't fit right and makes me I'm painting a picture in my head where institutional traders are off-loading onto irrational retail.
QIAGEN NV (QGEN) - GAP-FILL TRADEEntry Point: When price crosses above 50 DMA (blue line). This allows prices to take over 50 Week MA and 20 Month MA first.
Profit Taking: Around $40.50 when gap about to close
Stop Loss: When price crosses below 20 DMA to minimize heavy loss. For me, I will exit when price crosses below the supporting trend line.
Indicators are slightly bullish. Bollinger bands are expanding slightly, but not yet at a convincing manner.
Qiagen NV Bullish perspective Coronavirus Stock $qgenQGEN announced the shipping of its latest QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation purposes. The latest test kit helps detect the novel coronavirus SARS-CoV-2, thus adding rapid Sample to Insight syndromic testing to the company’s molecular testing solutions portfolio during the public health emergency.
Currently, QIAGEN is on track to ship QIAstat-Dx testing kits to public health institutions in other regions, including Europe, South-East Asia and the Middle East. Notably, the QIAstat-Dx system was introduced in Europe in 2018, after receiving the CE mark. The system was also cleared by the FDA in mid-2019.
Daily chart to follow.
Company profile
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
